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Abstract
Corin (an atrial natriuretic peptide–converting enzyme) represents a potential biomarker for gestational 
hypertensive disorders; yet, its role in blood pressure (BP) regulation throughout pregnancy remains unclear. We 
investigated the time course of change in blood corin content in relation to BP and sympathetic nerve activity 
throughout pregnancy. Forty-four women (29±0.9 years) participated. Following-term, 23 had low-risk (no 
personal history of gestational hypertensive disorders) normal pregnancies, 13 had high-risk (personal history of 
gestational hypertensive disorders) normal pregnancies, and 8 developed gestational hypertension. BP, heart 
rate, muscle sympathetic nerve activity, and serum corin were measured before pregnancy, during early (4–8 
weeks) and late pregnancy (32–36 weeks), and postpartum (6–10 weeks). Overall, compared with 
prepregnancy, corin remained unchanged during early pregnancy, increased markedly during late pregnancy 
(P<0.001), and returned to prepregnancy levels postpartum. In women who developed gestational hypertension, 
the change in corin from early to late pregnancy was greater than those with low-risk normal pregnancies (∆971
±134 versus ∆486±79 pg/mL; P<0.05). Throughout pregnancy, BP and muscle sympathetic nerve activity were 
augmented in women with gestational hypertension (all P<0.05). Finally, changes in corin from early to late 
pregnancy were related to all indices of BP (R=0.454–0.551; all P<0.01) in late pregnancy, whereas burst 
frequency, burst incidence, and total muscle sympathetic nerve activity (R=0.576–0.614; all P<0.001) in early 
pregnancy were related to changes in corin from early to late pregnancy. Corin plays a unique role in BP 
regulation throughout normotensive and, especially, hypertensive pregnancy and may represent a promising 
biomarker for determining women at high risk of adverse pregnancy outcome.
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Pregnancy-induced hypertensive disorders (ie, gestational hy-pertension and preeclampsia), which occur in ≈10% of all 
pregnancies,1,2 represent a major risk factor for maternal-fetal 
morbidity and mortality worldwide. Rather alarmingly, women 
with gestational hypertensive disorders (GHDs) have a higher 
risk of disease reoccurrence in subsequent pregnancies3 and, fur-
thermore, remain at an elevated risk of cardiovascular disease 
development in later life, including hypertension, ischemic heart 
disease, and stroke.4,5 However, the exact mechanisms and cause 
of GHDs remain elusive, owing largely to the heterogeneous and 
multifactorial nature of the disease. As such, this hinders early 
recognition and accurate diagnosis, and ultimately, effective pre-
ventative strategies and management of patients. Therefore, the 
study of potential evidence-based, preclinical biomarkers for the 
early prediction of risk for hypertensive pregnancy represents 
a critical endeavor towards the successful diagnosis, manage-
ment, and prevention of deleterious maternal-fetal outcome.
Corin is a transmembrane serine protease predominantly 
located in the heart, where it converts ANP (atrial natriuretic 
peptide) from its precursor peptide (ie, pro-ANP) to its bio-
logically active form, thereby stimulating natriuresis, diuresis, 
and vasodilation.6 Therefore, corin represents a key regulator 
of cardiovascular and renal function through its influence on 
blood pressure (BP) and salt-water balance, respectively.6 In 
recent years, corin has gathered much attention as a promising 
biomarker for cardiovascular disease,7 given its association 
with risk and outcome in many cardiac-related disorders (ie, 
hypertension, heart failure, myocardial infarction, stroke).8–14 
Interestingly, corin has also been found in the pregnant uterus, 
where it plays an important role in promoting trophoblast in-
vasion and spiral artery remodeling to ensure adequate utero-
placental perfusion.15 Recently, corin has been identified as a 
potential contributor to the pathogenesis of preeclampsia and 
hypertensive pregnancy; specifically, uterine Corin mRNA 
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and protein levels were lower in women with hypertensive 
pregnancies versus those with normotensive pregnancies.15 
However, somewhat serendipitously, Cui et al15 discovered 
that blood corin levels were actually higher in preeclamptic 
women than in those with normal pregnancies. Indeed, a small 
handful of studies (but not all) have since demonstrated ele-
vated blood corin in hypertensive pregnancy16–20; yet, values 
were measured at various, inconsistent times during preg-
nancy, and only one was longitudinal in nature.16 As such, 
there is limited data on the time course of change in blood 
(plasma or serum) corin levels throughout pregnancy and its 
association with resting BP and its regulatory mechanisms 
(ie, sympathetic nerve activity). Therefore, the role played by 
corin in neuro-cardiovascular control throughout pregnancy in 
humans, as well as the potential of corin as a biomarker of 
GHDs, remains to be determined.
Therefore, the purpose of the current study was to inves-
tigate, in a prospective manner, the time course of change in 
maternal blood corin content in relation to resting BP and 
sympathetic nerve activity throughout pregnancy in women. 
Specifically, we tested the hypothesis that greater increases in 
corin content throughout pregnancy would be associated with 
greater resting BP in late pregnancy.
Methods
The authors declare that all supporting data are available within the 
article.
Participants
Forty-four women who were planning to become pregnant or were 
within the first 8 weeks of pregnancy participated in the current inves-
tigation after providing informed written consent. Participants were 
nonsmokers and free of overt disease. Exclusion criteria included 
chronic hypertension, recreational drug use or hormonal contracep-
tives within the previous 6-months, hormonal fertility treatment or 
supplement use, and those women with irregular menstrual cycles. 
All experimental protocols were approved by the Institutional Review 
Boards at the University of Texas Southwestern Medical Center and 
Texas Health Presbyterian Hospital Dallas.
All women had singleton, full-term pregnancies. After term, 
participants were divided into 3 groups: (1) those women with 
low-risk (ie, no personal history of hypertensive pregnancy) nor-
mal pregnancies (LR-NP; n=23); (2) those women with high risk 
(ie, personal history of hypertensive pregnancy), yet normal preg-
nancies currently (HR-NP; n=13); and (3) those women who de-
veloped GHD after their late pregnancy testing (n=8).21 Of the 8 
women who developed gestational hypertension, 6 had a history of 
hypertensive pregnancy. Within the HR-NP group, 8 women had a 
personal history of gestational hypertension, 3 had a personal his-
tory of preeclampsia, 1 had a personal history of eclampsia, and 1 
had a personal history of HELLP syndrome (a variant of preeclamp-
sia characterized by hemolysis, elevated liver enzymes, and low 
platelet count). Data on pregnancy outcomes were obtained from 
the hospital maternity records of the women, and diagnoses were 
made based on the criteria of the American College of Obstetricians 
and Gynecologists Task Force on Hypertension in Pregnancy.22 
Specifically, gestational hypertension was defined as de novo hy-
pertension (ie, systolic BP ≥140 and diastolic BP ≥90 mm Hg) at 
≥20 weeks of gestation in the absence of proteinuria or new signs of 
end-organ dysfunction. All 8 women who developed gestational hy-
pertension during their pregnancies did so after their late pregnancy 
testing visit (see below). None of the women in the present study 
developed preeclampsia. Normal pregnancy was defined as those 
with the absence of GHDs or other pregnancy-related morbidities 
(ie, gestational diabetes mellitus).
Study Design and Protocol
Women were tested before pregnancy (midluteal phase; n=25), 
during early (4–8 weeks gestation; n=44) and late (32–36 weeks 
gestation; n=44) pregnancy, and postpartum (6–10 weeks postdeliv-
ery; n=43). Before each testing day, participants adhered to a 2-day 
isocaloric constant diet consisting of 150 mEq sodium, 100 mEq 
potassium, and 1000 mg calcium, whereas water intake was ad lib-
itum. Experiments were performed ≥2 hours after a light breakfast, 
and participants abstained from caffeine and alcohol for ≥48 hours 
and strenuous exercise for ≥24 hours before study participation. 
Studies were conducted in a quiet, environmentally controlled lab-
oratory with an ambient temperature of ≈25°C. All repeat testing 
was conducted at the same time of day. Pregnancy was confirmed 
each testing day by the measurement of β-human chorionic gonad-
otropin level.
Participants were studied in the resting supine (rotated ≈15° into 
the left lateral) position. An intravenous catheter was inserted into 
the antecubital vein of the left arm for blood samples. After at least 
30 minutes of supine rest, a blood sample was taken for the as-
sessment of corin content, followed by resting BP and heart rate 
(HR) measures. Finally, at least 10 minutes after a satisfactory nerve 
recording site had been found, baseline muscle sympathetic nerve 
activity (MSNA) was measured for 6 minutes during spontaneous 
breathing.
Experimental Measures and Analysis
Hemodynamics
HR was determined from lead II of the ECG. Resting BP was meas-
ured after at least a 30-minute rest via electrosphygmomanometry 
(SunTech Medical Instruments, Inc, Raleigh, NC), with a microphone 
placed over the brachial artery to detect Korotkoff sounds.23 Mean 
arterial BP was calculated as ([systolic BP−diastolic BP]/3+diastolic 
BP). The average of 3 BP measurements was used in the final analysis.
Muscle Sympathetic Nerve Activity
Sympathetic neural recordings were obtained in the right peroneal 
nerve by microneurography, using standard procedures as outlined 
originally by Hagbarth and Vallbo24 and used frequently in our 
hands25–27 (662C-3; Bioengineering of University of Iowa, Iowa City, 
IA). The level of integrated MSNA was quantified using burst fre-
quency (bursts/min) and burst incidence (bursts/100 heartbeats). 
Furthermore, burst amplitude (normalized within each individual to 
the largest burst, which was assigned a value of 100 arbitrary units) 
was determined for the calculation of total MSNA (product of burst 
frequency and normalized burst amplitude).
Corin
Maternal corin content was measured via ELISA (R&D Systems, 
Minneapolis, MN)28 by a trained investigator blinded to patient data 
and pregnancy outcome. In brief, microtiter plates were coated with 
an anticorin antibody. Next, serum samples or recombinant human 
corin protein standards were added and incubated at room tempera-
ture for 2 hours. The plates were washed 5× with a wash buffer, and 
a biotinylated antihuman corin antibody was added and incubated for 
another 2 hours. After 5 more washes, peroxidase-conjugated strepta-
vidin was added and incubated at room temperature for an additional 
30 minutes. The reaction was visualized by adding a horseradish per-
oxidase substrate (3,3′,5,5′-tetramethylbenzidine), and the optical 
density was monitored with a spectrometer at a wavelength of 450 
nm. We performed triplicate sample measurements and normalized 
them by first subtracting 550 nm absorbance values and then the av-
erage absorbance of blank wells. The within-individual typical error, 
expressed as coefficient of variation, for corin measurement was 
5.46%, and the correlation coefficient between the measurements 
was R=0.998.
Statistical Analysis
To determine sample size, we used previously published data on 
the mean difference and SD of maternal corin content (our pri-
mary variable of interest) between women with GHDs and women 
with normotensive pregnancies.17 From this work, we anticipated 
the smallest meaningful difference and SD in corin content to be 
550±450 pg/mL. Based on an assigned α of 0.05 and power of 0.80, 
an estimate of 42 participants in total was deemed sufficient.
One-way repeated measures ANOVA assessed the effect of preg-
nancy (pre to early to late to post) on maternal corin content in all 
participants. The delta change in corin levels from early to late preg-
nancy between groups was assessed using 1-way ANOVA. The ef-
fect of group and pregnancy on all neural-cardiovascular variables 
was assessed with a repeated measures analysis using linear mixed 
models. In addition to the overall average effect, the slope and in-
tercept were allowed to vary from participant to participant (random 
effect). Specifically, this model provides a more robust analysis of 
longitudinal data sets through its ability to accommodate missing data 
points and model nonlinear, individual characteristics.29 Bonferroni-
corrected post hoc procedures were used for all analyses, when ap-
plicable. Linear regression analyses were used to determine specific 
relationships between variables of interest. Statistical significance 
was set at P<0.05, and values are presented as mean±SEM. All sta-
tistical analyses were performed using SPSS Statistics (Version 23, 
Chicago, IL).
Results
Participant characteristics are shown in Table. Specifically, 
there were no differences in age or height between groups 
(both P>0.05), whereas weight was greater in GHD versus 
LR-NP and HR-NP throughout pregnancy (all P<0.05). 
Weight increased during early and late pregnancy (both 
P<0.001 versus pre); however, the magnitude of weight gain 
was not different between groups (P>0.05).
Compared with prepregnancy, corin levels remained un-
changed during early pregnancy, increased markedly during 
late pregnancy (P<0.001), and returned to prepregnancy lev-
els after delivery (Figure 1). In women who developed GHD 
during their pregnancies, the change in corin levels from 
early to late pregnancy was greater than in those with LR-NP 
(∆971±134 versus ∆486±79 pg/mL; P<0.05; Figure 1). Yet, 
no differences existed in the change in corin levels from early 
to late pregnancy between HR-NP (∆799±105 pg/mL) and 
both LR-NP and GHD groups (both P>0.05).
Figure 2 displays the changes in resting BP and HR 
throughout pregnancy. Before pregnancy, systolic BP was not 
different between groups (all P>0.05), whereas diastolic BP 
and mean arterial BP were greater in GHD versus LR-NP 
(both P<0.05). In all groups, systolic and mean arterial BP 
increased from early to late pregnancy (all P<0.05 versus 
early) and returned to prepregnancy levels after delivery (all 
P>0.05 versus pre). Conversely, diastolic BP was unchanged
throughout pregnancy in LR-NP and HR-NP women (all
P>0.05). In GHD, diastolic BP decreased during early preg-
nancy (P<0.05 versus pre), increased from early to late preg-
nancy (P<0.05 versus early), and remained at prepregnancy
levels postpartum (P>0.05 versus pre). In women who devel-
oped GHD, systolic BP was greater than LR-NP throughout
early and late pregnancy and postpartum, whereas diastolic
BP and mean arterial BP were elevated at late and postpreg-
nancy (all P<0.05). Furthermore, after delivery, HR-NP had
greater diastolic BP and mean arterial BP as compared to
LR-NP (both P<0.05). In all groups, resting HR increased
during late pregnancy (all P<0.05 versus pre). After delivery,
HR was decreased below prepregnancy levels in LR-NP
and HR-NP (both P<0.05 versus pre) but was not different
in GHD (P>0.05 versus pre). Throughout pregnancy, both 
HR-NP and GHD groups had greater resting HR than LR-NP 
(all P<0.05).
Figure 3 displays the changes in MSNA throughout preg-
nancy. Before pregnancy, all indices of MSNA were similar 
between groups (all P>0.05). Burst frequency, burst inci-
dence, and total MSNA were increased during late pregnancy 
(all P<0.05 versus pre) yet returned to prepregnancy levels 
postpartum (all P>0.05 versus pre). Throughout early and 
late pregnancy, as well as postpartum, all indices of MSNA 
were greater in women with GHD than in HR-NP and LR-NP 
groups (all P<0.05).
As shown in Figure 4, the change in corin from early to late 
pregnancy was related significantly to systolic BP (R=0.513; 
P<0.001), diastolic BP (R=0.454; P<0.01), and mean arte-
rial BP (R=0.551; P<0.001) in late pregnancy. Furthermore, 
the change in corin from early to late pregnancy was related 
Table. Participant Characteristics
Characteristic
All LR-NP HR-NP GHD
(N=44) (n=23) (n=13) (n=8)
Gestation, wk
 Pre … … … …
 Early 7.2±0.2 6.8±0.3 7.2±0.5 8.2±0.7
 Late 34.1±0.2 34.4±0.2 33.8±0.4 33.8±0.5
 Post 8.3±0.2 8.3±0.3 8.6±0.4 8.0±0.5
Age, y
 Pre 30±0.9 30±0.9 31±1.2 29±1.5
 Early 30±0.7 31±0.9 31±1.2 29±1.5
 Late 31±0.7 31±0.9 32±1.2 30±1.5
 Post 31±0.6 31±0.9 32±1.2 30±1.5
Height, cm
 Pre 163.8±1.2 163.8±1.6 163.4±2.1 164.2±2.7
 Early 163.4±1.2 163.4±1.6 162.6±2.1 164.3±2.7
 Late 163.8±1.2 163.9±1.6 163.1±2.1 164.6±2.7
 Post 163.5±1.2 163.6±1.6 162.9±2.1 164.1±2.7
Weight, kg
 Pre 73.3±3.0 60.5±3.8 71.3±5.0 88.0±6.3*†
 Early 74.4±2.9 61.9±3.7 72.3±4.9 89.2±6.3*†
 Late 85.6±2.9‡ 73.1±3.7‡ 82.3±5.0‡ 101.3±6.3‡*†
 Post 78.6±2.9‡ 66.4±3.7‡ 75.6±4.9‡ 93.94±6.3‡*†
Racial origin, n (%)
 White 26 (59.1) 10 (43.5) 11 (84.6) 5 (62.5)
 Black 5 (11.4) 3 (13.0) … 2 (25.0)
 Asian 8 (18.2) 7 (30.4) … 1 (12.5)
 Hispanic 5 (11.4) 3 (13.0) 2 (15.4) …
Values are mean±SEM. GHD indicates gestational hypertensive disorder; HR-
NP, high-risk normal pregnancy; and LR-NP, low-risk normal pregnancy.
*Significantly different than LR-NP, P<0.05.
†Significantly different than HR-NP, P<0.05.
‡Significantly different from prepregnancy, P<0.01.
moderately to burst frequency (R=0.349; P<0.05), burst in-
cidence (R=0.338; P<0.05), and total MSNA (R=0.393; 
P<0.01) in late pregnancy. However, as shown in Figure 5, 
burst frequency (R=0.614; P<0.001), burst incidence 
(R=0.576; P<0.001), and total MSNA (R=0.606; P<0.001) 
in early pregnancy were related strongly to changes in corin 
from early to late pregnancy.
Discussion
To our knowledge, this is the first longitudinal study to dem-
onstrate that changes in maternal corin content from early 
to late pregnancy are associated directly with resting BP 
in late pregnancy and levels of sympathetic nerve activity 
in early and late pregnancy. Furthermore, women who de-
velop gestational hypertension display greater increases in 
corin content during pregnancy as compared to their normo-
tensive counterparts, in addition to elevated resting BP and 
exaggerated sympathetic nerve activity. Our results suggest 
that corin plays a unique role in BP regulation throughout 
normotensive and especially hypertensive pregnancy, and 
furthermore, may represent a novel biomarker for the early 
recognition of those women at risk for gestational hyperten-
sion development.
Corin and BP Regulation in Pregnancy
Corin plays an important role in cardiovascular control through 
its regulation of blood volume and BP.6 Interestingly, corin 
has been shown to be markedly upregulated in the decidua of 
the pregnant uterus15 but is not detected in the nonpregnant 
uterus,30 suggesting a role as a local adaptive mechanism to en-
sure adequate hemodynamic homeostasis in early pregnancy. 
Indeed, as demonstrated by Cui et al,15 corin expression in the 
uterus is essential to the development of an adequate uteropla-
cental vascular circuit through its involvement in spiral artery 
remodeling. In this sense, corin seems to be involved in the 
pathogenesis of hypertensive pregnancy. Specifically, when 
uterine corin levels are low, preeclampsia and gestational hy-
pertension ensue.15 However, somewhat paradoxically, a small 
but growing body of literature demonstrates that corin levels 
in the blood are elevated in hypertensive pregnancies.15–20 Our 
present findings support this conjecture. Therefore, it seems 
that corin represents a key regulatory mechanism of arterial 
BP control throughout pregnancy in humans and, furthermore, 
may have a unique involvement in the cause of gestational 
hypertension.
Furthermore, we extend current knowledge on the relation-
ship between corin and BP control during pregnancy to show 
for the first time in a prospective manner that changes in corin 
content from early to late pregnancy are related positively to 
levels of resting BP in late pregnancy. Previously, Liu et al18 
investigated plasma corin levels during midpregnancy (16–20 
weeks gestation) in patients who subsequently developed 
hypertensive pregnancies versus normal pregnant controls. 
Specifically, women were categorized into quartiles based on 
corin content, and when compared with the lowest corin quar-
tile, those in the highest quartile demonstrated significantly el-
evated risk for hypertensive pregnancy. Similarly, Miyazaki et 
al19 compared blood samples taken at delivery in women with 
Figure 1. Maternal corin content throughout 
pregnancy. Left, Maternal corin content at 
pre, early, late, and postpregnancy. Right, The 
change in corin from early to late pregnancy 
in low-risk normal pregnancy (LR-NP), high-
risk normal pregnancy (HR-NP), and women 
who developed gestational hypertensive 
disorder (GHD). *Significantly different from 
prepregnancy, P<0.001. †Significantly different 
from early pregnancy, P<0.001. αSignificantly 
different than LR-NP, P<0.05.
Figure 2. Resting blood pressure (BP) and 
heart rate at pre, early, late, and postpregnancy 
in low-risk normal pregnancy (LR-NP), high-
risk normal pregnancy (HR-NP), and women 
who developed gestational hypertensive 
disorder (GHD). *Significantly different from 
prepregnancy, P<0.05. †Significantly different 
from early pregnancy, P<0.05. αSignificantly 
different than LR-NP, P<0.05.
and without preeclampsia, and not only were plasma corin lev-
els higher in preeclamptic patients but also its concentrations 
were correlated positively with resting BP. Most recently, Gu 
et al20 demonstrated greater plasma corin at late pregnancy in 
women with mild and severe preeclampsia than in normoten-
sive women. Although these findings suggest an important role 
for corin in human pregnancy, the cross-sectional nature of 
these studies (and varying time points in which corin content 
was measured) prevent conclusions about the time course or 
causal relationship between maternal corin content and resting 
BP. In turn, this precludes judgment as to the potential effi-
cacy of corin as a biomarker of GHDs. In the only other lon-
gitudinal study, Khalil et al16 found no differences in plasma 
corin levels at midpregnancy between women with gestational 
hypertension or preeclampsia at term and normotensive con-
trols (was lower in preterm preeclampsia), yet levels in all 
groups increased rapidly as pregnancy progressed. Therefore, 
in line with our current findings, it seems that the (magnitude 
of) change in plasma or serum corin throughout pregnancy 
exerts greater influence on late pregnancy BP and subsequent 
pregnancy outcome. Indeed, we demonstrate that women 
who develop gestational hypertension experience the greatest 
increases in corin content during pregnancy, while a greater 
change in early to late maternal corin is associated significantly 
Figure 3. Muscle sympathetic nerve activity (MSNA) at pre, early, late, and 
postpregnancy in low-risk normal pregnancy (LR-NP), high-risk normal 
pregnancy (HR-NP), and women who developed gestational hypertensive 
disorder (GHD). *Significantly different from prepregnancy, P<0.05. 
αSignificantly different than LR-NP, P<0.05. βSignificantly different from 
HR-NP, P<0.05. AU indicates arbitrary units.
Figure 4. Relationship between the change in corin from early to late 
pregnancy and resting blood pressure (BP) in late pregnancy in low-risk 
normal pregnancy (LR-NP), high-risk normal pregnancy (HR-NP), and 
women who developed gestational hypertensive disorder (GHD).
with elevated late pregnancy BP (R=0.551; P<0.001 for mean 
arterial BP). As such, the current study highlights the prom-
ising potential for corin to be used as a preclinical biomarker 
for determining women at risk for hypertensive pregnancy.
Sympathetic Nerve Activity in Hypertensive 
Pregnancy
In the present study, women who developed gestational hy-
pertension displayed markedly elevated sympathetic nerve ac-
tivity in early and late pregnancy. Furthermore, sympathetic 
nerve activity in early pregnancy was related strongly to the 
change in corin levels throughout pregnancy, which was ul-
timately related to arterial BP in late pregnancy. Certainly, 
pregnancy is associated with dramatic changes in maternal 
hemodynamics, most notably highlighted by a rise in car-
diac output and a fall in systemic vascular resistance.31,32 Both 
cross-sectional33–35 and longitudinal25,26,36 studies have dem-
onstrated elevated sympathetic nerve activity (in the range of 
50%–150%) throughout normal pregnancy. It is thought that 
this sympathetic hyperactivity helps to counteract the signif-
icant fall in systemic vascular resistance and keep resting BP 
at prepregnancy levels. However, when excessive sympathetic 
activation occurs, GHDs likely manifest.37–40 Our present find-
ings support this view. Specifically, all indices of MSNA were 
augmented in early and late pregnancy in the GHD group. It is 
perhaps likely then that maternal corin content increased to a 
greater extent in these women as an adaptive reaction to sym-
pathetic hyperactivity and oncoming high BP. Indeed, ANP 
exerts sympathoinhibitory effects in humans.41 Furthermore, 
it is worth noting that MSNA was not (statistically) increased 
during early pregnancy presently, which differs from our pre-
vious work.25,26 Although the reason for this discrepancy is 
unclear, it may be because of the robustness and more conser-
vative nature of the linear mixed model design used in the cur-
rent analysis, versus paired26 and unpaired25 t test comparisons 
of the pre to early response used previously. Specifically, of 
the 25 women with pre and early pregnancy MSNA data in our 
current study, 75% experienced an increase in MSNA burst 
frequency in early pregnancy (15±2 to 19±2 bursts/min for all 
25 women; P=0.048 using paired t test).
Potential Mechanisms for Corin Response During 
Pregnancy
Our results provide novel evidence with respect to the asso-
ciation between the magnitude of corin increase throughout 
pregnancy and elevated resting BP and risk of GHD develop-
ment. Although beyond the scope of the current investigation, 
the potential mechanisms mediating the increase in maternal 
corin content during pregnancy warrants some discussion. As 
mentioned, preeclamptic and hypertensive pregnancies are 
characterized by low uterine Corin mRNA and protein levels 
and impaired spiral artery remodeling in early pregnancy.15 
Therefore, as it relates to our present findings, perhaps those 
women destined for higher BP in late pregnancy (and GHD 
development) display greater increases in blood corin con-
tent (probably derived from the heart) during pregnancy as 
a compensatory response to decreased corin expression in 
uterine tissue. Additionally, corin concentration may be ele-
vated in the circulation as a homeostatic response to elevated 
sympathetic nerve activity and increasing arterial BP during 
pregnancy (ie, in an attempt to rescue high or increasing BP 
levels). Inferring from our own data, both the change in mean 
arterial BP from early to late pregnancy (R=0.564; P<0.001; 
data not reported) and early pregnancy MSNA burst frequency 
Figure 5. Relationship between muscle sympathetic nerve activity (MSNA) 
in early pregnancy and the change in corin from early to late pregnancy in 
low-risk normal pregnancy (LR-NP), high-risk normal pregnancy (HR-NP), 
and women who developed gestational hypertensive disorder (GHD). AU 
indicates arbitrary units.
(R=0.614; P<0.001) were related directly to the increase in 
corin content throughout pregnancy. Certainly, elevated 
blood corin levels have been found in chronic hypertension.14 
However, Miyazaki et al19 reported elevated corin even in 
normotensive pregnancy complicated with fetal growth re-
striction, suggesting that other factors are also in play. Even 
so, this begs the question as to why BP is not lowered in re-
sponse to elevated corin in late pregnancy. Recently, it was 
found that while plasma corin was elevated in mild and severe 
preeclampsia, NPR (natriuretic peptide receptor)-A expres-
sion was downregulated and NPR-C expression was upregu-
lated, thereby inhibiting the vasorelaxant effects of ANP and 
increasing ANP clearance and degradation in these patients, 
respectively.20 Certainly, these unresolved matters require fu-
ture investigation.
Study Limitations
First, the number of patients with GHD is relatively small, 
and no women developed preeclampsia. However, this limita-
tion is difficult to avoid given the logistical difficulties in per-
forming longitudinal studies in pregnant women and the lack 
of control in determining pregnancy outcome. Nevertheless, 
to our knowledge, this is the only prospective study to ex-
amine neuro-cardiovascular control throughout pregnancy 
in women with GHD. Second, weight was greater in women 
with GHD before and throughout pregnancy (although weight 
gain did not differ), and corin levels have been shown to be 
moderately elevated in obese individuals.42 Yet, our data sug-
gest that corin levels were not related to weight before or 
during pregnancy. Third, there were differences in racial dis-
tribution between groups, and the effect of race on corin in 
pregnancy is unknown. Previously, Khalil et al16 found lower 
corin levels in women of Afro-Carribean origin as compared 
to white women. Although we studied a limited number of 
Asians (n=8), blacks (n=5), and Hispanics (n=5), as compared 
to white women (n=26), there did not seem to be any effect of 
race on maternal corin content. Finally, we did not measure 
levels of circulating ANP or pro-ANP in our current cohort, 
yet previous investigations demonstrate similarly elevated 
plasma levels of ANP and pro-ANP in women with gesta-
tional hypertension.6
Perspectives
GHDs are associated with a dramatic increase in risk of ad-
verse maternal-fetal outcome. Certainly, hypertensive preg-
nancies are a leading cause of maternal-fetal morbidity and 
mortality acutely; yet, their presence also infers increased risk 
of future cardiovascular disease development.4,5 Furthermore, 
preeclampsia is now recognized as an independent risk factor 
for cardiovascular disease mortality.43 Currently, management 
and treatment strategies remain limited, owing largely to the 
multifactorial nature of the disease. Fundamentally, GHDs 
reflect an inherent failure in properly regulating arterial BP 
homeostasis throughout pregnancy. Our present findings dem-
onstrating the unique involvement of corin in neuro-circula-
tory control throughout pregnancy offers an exciting new take 
on an enigmatic disease. Specifically, we show for the first 
time that the change in corin content from early to late preg-
nancy is related directly to resting BP levels in late pregnancy, 
suggesting that maternal corin content may represent a novel 
target in the ongoing investigation of useful biomarkers for de-
termining women at high risk of adverse pregnancy outcome.
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What Is New?
• This is the first longitudinal study to demonstrate that changes in ma-
ternal corin content from early to late pregnancy are related directly to
arterial blood pressure in late pregnancy and levels of sympathetic nerve 
activity in early and late pregnancy.
• Women who develop gestational hypertension display greater increases
in corin content as compared to normal pregnancy, in addition to ele-
vated resting blood pressure and exaggerated sympathetic nerve activity.
What Is Relevant?
• Gestational hypertensive disorders are associated with a dramatic in-
crease in risk of adverse maternal-fetal outcome. Our results suggest
that corin plays a unique role in blood pressure regulation throughout
normotensive and especially hypertensive pregnancy and, furthermore,
may represent a promising biomarker for hypertensive pregnancy.
Summary
We show for the first time here that the change in corin content 
throughout pregnancy is related directly to blood pressure levels in 
late pregnancy, suggesting that maternal corin content may repre-
sent a useful biomarker for the determination of those women at 
high risk of adverse pregnancy outcome.
Novelty and Significance
